Advertisement
Screener

Alkermes plc. (ALKS) Revenue Breakdown

2.8 / 5 stars · 68/120 Roast Me

Alkermes plc. Revenue Breakdown

No Revenue Breakdown for ALKS on this site yet.

  • 2025-12-31: Others Not split by product in the filing$1.48B100.00%; Total revenue $1.48B.
  • 2024-12-31: Others Not split by product in the filing$1.56B100.00%; Total revenue $1.56B.
  • 2023-12-31: Others Not split by product in the filing$1.66B100.00%; Total revenue $1.66B.
  • 2022-12-31: Others Not split by product in the filing$1.11B100.00%; Total revenue $1.11B.

Source checked: the stored Revenue Breakdown page for ALKS.

Revenue by product

Each year (12 month)

Fiscal year endOthersTotal revenue
2025-12-31
Not split by product in the filing
$1.48B
100.00%
$1.48B
2024-12-31
Not split by product in the filing
$1.56B
100.00%
$1.56B
2023-12-31
Not split by product in the filing
$1.66B
100.00%
$1.66B
2022-12-31
Not split by product in the filing
$1.11B
100.00%
$1.11B
2021-12-31
Not split by product in the filing
$1.17B
100.00%
$1.17B
2020-12-31
Not split by product in the filing
$1.04B
100.00%
$1.04B
2019-12-31
Not split by product in the filing
$1.17B
100.00%
$1.17B
2018-12-31
Not split by product in the filing
$1.09B
100.00%
$1.09B
2017-12-31
Not split by product in the filing
$903.37M
100.00%
$903.37M
2016-12-31
Not split by product in the filing
$745.69M
100.00%
$745.69M
2015-12-31
Not split by product in the filing
$628.34M
100.00%
$628.34M
2014-12-31
Not split by product in the filing
$618.79M
100.00%
$618.79M
2013-12-31
Not split by product in the filing
$596.33M
100.00%
$596.33M
2013-03-31
Not split by product in the filing
$575.55M
100.00%
$575.55M
2012-03-31
Not split by product in the filing
$389.98M
100.00%
$389.98M
2011-03-31
Not split by product in the filing
$186.64M
100.00%
$186.64M
2010-03-31
Not split by product in the filing
$178.28M
100.00%
$178.28M

Each quarter (3 month)

Quarter endOthersTotal revenue
2026-06-30
Not split by product
$496.01M
100.00%
$496.01M
2026-03-31
Not split by product
$392.91M
100.00%
$392.91M
2025-12-31
Not split by product
$384.55M
100.00%
$384.55M
2025-09-30
Not split by product
$394.19M
100.00%
$394.19M
2025-06-30
Not split by product
$390.66M
100.00%
$390.66M
2025-03-31
Not split by product
$306.51M
100.00%
$306.51M
2024-12-31
Not split by product
$429.99M
100.00%
$429.99M
2024-09-30
Not split by product
$378.14M
100.00%
$378.14M
2024-06-30
Not split by product
$399.13M
100.00%
$399.13M
2024-03-31
Not split by product
$350.37M
100.00%
$350.37M
2023-12-31
Not split by product
$377.48M
100.00%
$377.48M
2023-09-30
Not split by product
$380.94M
100.00%
$380.94M
2023-06-30
Not split by product
$617.40M
100.00%
$617.40M
2023-03-31
Not split by product
$287.60M
100.00%
$287.60M
2022-12-31
Not split by product
$304.67M
100.00%
$304.67M
2022-09-30
Not split by product
$252.36M
100.00%
$252.36M
2022-06-30
Not split by product
$276.22M
100.00%
$276.22M
2022-03-31
Not split by product
$278.55M
100.00%
$278.55M
2021-12-31
Not split by product
$324.46M
100.00%
$324.46M
2021-09-30
Not split by product
$294.14M
100.00%
$294.14M
2021-06-30
Not split by product
$303.72M
100.00%
$303.72M
2021-03-31
Not split by product
$251.43M
100.00%
$251.43M
2020-12-31
Not split by product
$280.00M
100.00%
$280.00M
2020-09-30
Not split by product
$265.01M
100.00%
$265.01M
2020-06-30
Not split by product
$247.53M
100.00%
$247.53M
2020-03-31
Not split by product
$246.22M
100.00%
$246.22M
2019-12-31
Not split by product
$412.73M
100.00%
$412.73M
2019-09-30
Not split by product
$255.24M
100.00%
$255.24M
2019-06-30
Not split by product
$279.87M
100.00%
$279.87M
2019-03-31
Not split by product
$223.10M
100.00%
$223.10M
2018-12-31
Not split by product
$315.76M
100.00%
$315.76M
2018-09-30
Not split by product
$248.72M
100.00%
$248.72M
2018-06-30
Not split by product
$304.64M
100.00%
$304.64M
2018-03-31
Not split by product
$225.15M
100.00%
$225.15M
2017-12-31
Not split by product
$275.37M
100.00%
$275.37M
2017-09-30
Not split by product
$217.38M
100.00%
$217.38M
2017-06-30
Not split by product
$218.84M
100.00%
$218.84M
2017-03-31
Not split by product
$191.78M
100.00%
$191.78M
2016-12-31
Not split by product
$213.51M
100.00%
$213.51M
2016-09-30
Not split by product
$180.24M
100.00%
$180.24M
2016-06-30
Not split by product
$195.16M
100.00%
$195.16M
2016-03-31
Not split by product
$156.77M
100.00%
$156.77M
2015-12-31
Not split by product
$163.10M
100.00%
$163.10M
2015-09-30
Not split by product
$152.65M
100.00%
$152.65M
2015-06-30
Not split by product
$151.37M
100.00%
$151.37M
2015-03-31
Not split by product
$161.21M
100.00%
$161.21M
2014-12-31
Not split by product
$175.16M
100.00%
$175.16M
2014-09-30
Not split by product
$159.99M
100.00%
$159.99M
2014-06-30
Not split by product
$153.42M
100.00%
$153.42M
2014-03-31
Not split by product
$130.21M
100.00%
$130.21M
2013-12-31
Not split by product
$154.48M
100.00%
$154.48M
2013-09-30
Not split by product
$139.80M
100.00%
$139.80M
2013-06-30
Not split by product
$138.63M
100.00%
$138.63M
2013-03-31
Not split by product
$163.42M
100.00%
$163.42M
2012-12-31
Not split by product
$135.91M
100.00%
$135.91M
2012-09-30
Not split by product
$123.98M
100.00%
$123.98M
2012-06-30
Not split by product
$152.24M
100.00%
$152.24M
2012-03-31
Not split by product
$130.47M
100.00%
$130.47M
2011-12-31
Not split by product
$125.64M
100.00%
$125.64M
2011-09-30
Not split by product
$71.98M
100.00%
$71.98M
2011-06-30
Not split by product
$61.88M
100.00%
$61.88M
2011-03-31
Not split by product
$51.14M
100.00%
$51.14M
2010-12-31
Not split by product
$43.98M
100.00%
$43.98M
2010-09-30
Not split by product
$49.25M
100.00%
$49.25M

Similar stocks

Stock NameCountryMarket CapPE Ratio
RHYTHM PHARMACEUTICALS, INC. (RYTM)United States$6.771B-37.20
IONIS PHARMACEUTICALS INC (IONS)United States$7.277B-23.25
Liquidia Corp (LQDA)United States$6.347B51.23
Amneal Pharmaceuticals, Inc. (AMRX)$6.326B25.62
Spyre Therapeutics, Inc. (SYRE)United States$7.685B-43.69
Structure Therapeutics Inc. (GPCR)United States$7.710B-53.41
Praxis Precision Medicines, Inc. (PRAX)United States$7.884B-27.60
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76